用于肿瘤光热/分子靶向双向协同治疗的聚合物胶束研究

基本信息
批准号:51473109
项目类别:面上项目
资助金额:83.00
负责人:陈华兵
学科分类:
依托单位:苏州大学
批准年份:2014
结题年份:2018
起止时间:2015-01-01 - 2018-12-31
项目状态: 已结题
项目参与者:刘欢欢,朱爱军,袁志强,郭苗,杨涛,李艳丽
关键词:
pH响应光热治疗协同效应聚合物胶束分子靶向治疗
结项摘要

It is a major challenge to achieve highly efficient anticancer efficacy for cancer therapy. The nanoparticles with synergistic anticancer efficacy are considered as a new promising focus in this field. In this application, we propose to synthesize poly(ethylene glycol)-b-poly(L-cysteine)-b-poly(L- aspartic acid) triblock copolymer, and then develop pH-responsive core-cross-linked polymeric micelles with the bidirectional synergistic effects of photothermal and molecularly targeted therapies, in which photothermal Cypate is cross-linked within poly(L-aspartic acid) segment as inner hydrophobic cores, and 17-(Allylamino) -17-demethoxygeldanamycin (17-AAG), a heat shock protein 90 (HSP90) inhibitor is also encapsulated within poly(L-cysteine)segment as exterior hydrophobic cores.The physicochemical properties of the micelles are optimized to achieve effective cancer targeting effect and enhanced cellular uptake.The pH-responsive micelles can induce the enhanced release of 17-AAG in response to lysosomal environment, aviod the release of Cypate from the micelles owing to the cross-linked cores and thus improve the photostability of Cypate. Meanwhile, Cypate within the micellar cores causes remarkable photothermal therapy upon photoirradiation and also induce the disruption of lysosomes, which facilitates the translocation of 17-AAG into cytoplasm and thus enhances the cyototxicity of 17-AAG against tumor cells via the highly effective interaction with HSP90. Moreover, 17-AAG is able to inhibit the ability of HSP90 to repair the photothermal damage and therefore improve the photothermal therapy of Cypate in return. This work is highly valuable to explore efficient anticancer formulation with low adverse side effect and novel synergistic strategy for cancer therapy as well.

肿瘤的高效治疗是肿瘤治疗领域的难点,构建具有肿瘤协同治疗效应的纳米粒是该领域的新方向。本项目拟合成聚乙二醇-b-聚半胱氨酸-b-聚天冬氨酸聚合物,通过光热治疗药物Cypate与聚天冬氨酸侧链的交联形成胶束疏水内核,在聚半胱氨酸侧链引入pH响应基团,形成胶束疏水外核,并包载热休克蛋白90(HSP90)抑制剂17-AAG,构建出具有光热、分子靶向治疗双向协同效应的载药胶束。通过调控胶束的理化特征,增强其肿瘤靶向、细胞摄取能力;胶束进入溶酶体后响应释放17-AAG,而通过交联作用避免Cypate的释放,增强其光稳定性;在光激发下胶束中Cypate产生显著的光热治疗作用,同时诱导溶酶体破裂,促进17-AAG的胞浆分布以及与HSP90的结合,增强其分子靶向治疗作用,并降低细胞热损伤修复能力,从而反向增强光热治疗效果。本项目对探索高效、低毒的抗肿瘤制剂以及新的协同治疗策略具有重要理论意义和实用价值。

项目摘要

课题负责人制备了载药聚合物纳米粒,增强药物的光热治疗作用,并提高了药物的胞内递送能力,发展出高效的肿瘤热疗与分子靶向治疗的协同治疗策略。纳米粒在胞内释放药物,并通过碳菁染料产生的活性氧自由基(ROS)破坏溶酶体促进胞浆转运,从而增强分子靶向药物如17AAG的分子靶向治疗效应;同时,分子靶向药物17AAG明显抑制了肿瘤细胞受热应激性过表达的热休克蛋白90,从而降低细胞的热耐受性,进而增强了碳菁染料光热效应对肿瘤细胞的光热损伤作用。这种双向协同增效通过更强的细胞凋亡和坏死效应,显著提升了纳米粒对肿瘤细胞的协同治疗效应,实现了肿瘤的消融。在项目的支持下,课题负责人作为通讯作者在Adv Mater、ACS Nano、Adv Funct Mater等高水平国际期刊发表SCI论文13篇,其中影响因子大于10的论文12篇,项目编号第一标注论文3篇;获授权中国发明专利3项。

项目成果
{{index+1}}

{{i.achievement_title}}

{{i.achievement_title}}

DOI:{{i.doi}}
发表时间:{{i.publish_year}}

暂无此项成果

数据更新时间:2023-05-31

其他相关文献

1

Nucleolin targeting AS1411 aptamer modified pH-sensitive micelles for enhanced delivery and antitumor efficacy of paclitaxel

Nucleolin targeting AS1411 aptamer modified pH-sensitive micelles for enhanced delivery and antitumor efficacy of paclitaxel

DOI:10.1007/s12274-014-0619-4
发表时间:2015
2

视网膜母细胞瘤的治疗研究进展

视网膜母细胞瘤的治疗研究进展

DOI:
发表时间:2018
3

结核性胸膜炎分子及生化免疫学诊断研究进展

结核性胸膜炎分子及生化免疫学诊断研究进展

DOI:10.3760/cma.j.issn.1674-2397.2020.05.013
发表时间:2020
4

基于余量谐波平衡的两质点动力学系统振动频率与响应分析

基于余量谐波平衡的两质点动力学系统振动频率与响应分析

DOI:10.6052/1672⁃6553⁃2017⁃059
发表时间:2018
5

响应面法优化藤茶总黄酮的提取工艺

响应面法优化藤茶总黄酮的提取工艺

DOI:
发表时间:2015

相似国自然基金

1

肿瘤特异靶向的长循环多功能纳米胶束用于肝癌的光声成像及光热/光动力协同治疗研究

批准号:61575044
批准年份:2015
负责人:刘小龙
学科分类:F0511
资助金额:60.00
项目类别:面上项目
2

用于肿瘤光动力/光热协同治疗的低氧依赖性聚合物囊泡研究

批准号:51873143
批准年份:2018
负责人:陈华兵
学科分类:E0308
资助金额:59.00
项目类别:面上项目
3

iRGD多肽分子导向的核可逆交联的智能型胶束用于肿瘤靶向治疗

批准号:51173126
批准年份:2011
负责人:钟志远
学科分类:E0308
资助金额:65.00
项目类别:面上项目
4

基于壳核结构的磁性纳米胶束用于肿瘤靶向治疗及MRI监测

批准号:81171392
批准年份:2011
负责人:郭亮
学科分类:H2706
资助金额:14.00
项目类别:面上项目